Key result
Rivaroxaban plus aspirin reduces a net composite of MACE, MALE, and severe bleeding by ~28%.
Why the study?
Does rivaroxaban plus aspirin reduce the risk of cardiovascular and limb outcomes in patients with peripheral artery disease?
Does rivaroxaban plus aspirin reduce the risk of cardiovascular and limb outcomes in patients with peripheral artery disease?
Effect estimate: HR 0.72 (95% CI 0.59-0.87)
The combination of rivaroxaban and aspirin provides comprehensive protection against cardiovascular and limb outcomes in high-risk patients with peripheral artery disease.
May support rivaroxaban plus aspirin in high-risk PAD; leaves open confirmatory RCTs given low-certainty evidence.
aspirin) markedly reduced the risk of both CV and limb outcomes, and related complications, with a good safety profile. In fact, the net clinical benefit outcome composed of MACE; MALE, including major amputation, and fatal or critical organ bleeding was significantly reduced by 28% with the COMPASS strategy, (hazard ratio: 0.72; 95% confidence interval: 0.59-0.87). Therefore, the rivaroxaban plus aspirin approach provides comprehensive protection and should be considered for most patients with PAD at high risk of such events.
No takes yet. Share an insight, caveat, or question.
Hernández et al. (2020) conducted a review in Peripheral artery disease (PAD). Rivaroxaban plus aspirin was evaluated on Net clinical benefit outcome composed of MACE; MALE, including major amputation, and fatal or critical organ bleeding (HR 0.72, 95% CI 0.59-0.87). The rivaroxaban plus aspirin approach significantly reduced the net clinical benefit outcome composed of MACE, MALE, and fatal or critical organ bleeding by 28% (HR 0.72; 95% CI 0.59-0.87).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: